Glutathione and metallothionein in neurodegeneration-neuroprotection of Parkinson's disease

Neuroendocrinology Letters

Volumn 18, Issue 2-3, 1997, Pages 111-121

  Ebadi, Manuchair ^a   Rodriguez Sierra, Jorge F ^a   Norton, Neil S ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BRAIN DERIVED NEUROTROPHIC FACTOR; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE RECEPTOR; FERRITIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; HYDROGEN PEROXIDE; MAZINDOL; METALLOTHIONEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; OXIDOPAMINE; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SELEGILINE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

AKINESIA; BODY POSTURE; CONFERENCE PAPER; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; HUMAN; MUSCLE RIGIDITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RECEPTOR BLOCKING; SUBSTANTIA NIGRA; TREMOR;

EID: 0031429567     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Barbeau, A. (1961) Biochemistry of Parkinson's disease. In: Int. Congr. Neurol. Rome. p. 152, ed. G. Alema. Excerpta Medica: Amsterdam.
2. Birkmayer, W. and Hornykiewicz, O. (1961) Der L-3,4-dioxyphenylalanin (L-Dopa) effekt bei der Parkinson akinese. Wien. Klin. Wochenschr. 73, 787-788.
3. Chiba, K., Trevor, A. and Castagnoli, N. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Comm. 120, 574-578.
4. Cohen, G., Pasik, P., Cohen, B., Leist, A., Mytilineou, C. and Yahr, M. D. (1985) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106, 209-214.
5. Cohen, G., Farooqui, R. and Kesler, N. (1997) Parkinson disease: A new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA 94, 4890-4894.
6. D'Amato, R, J., Alexander, G. M., Schwartzman, R. J., Kitt, C. A., Price, D. L. and Snyder, S. H. (1987a) Evidence for neuromelanin involvement in MPTP induced neurotoxicity. Nature 327, 324-326.
7. D'Amato, R. J., Benham, D. F. and Snyder, S. H. (1987b) Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of Parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. J. Neurochem. 48, 653-658.
8. De Erausquin, G. A., Costa, E. and Hanbauer, I. (1994) Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease. Pharmacol. Rev. 46, 467-482.
9. Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P. and Marsden, C. D. (1987) Increased nigral iron content in postmortem Parkinsonian brain. Lancet 2, 1219-1220.
10. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P. and Marsden, C. D. (1989a) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem 52, 381-389.
11. Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P. and Marsden, C. D. (1989b) Increased nigra iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
12. Dexter, D. T., Carayon, A. and Vidailhet, M. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20.
13. Dexter, D. T., Carayon, A. and Javoy-Agid, F. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
14. Ebadi, M. (1991) Metallothionein and other zinc-binding proteins in brain. Meth. Enzym. 205, 363-387.
15. Ebadi, M., Hao, R., Cerutis, D. R., Blaxall, H. S., Pfeiffer, R. F., Rodriguez-Sierra, J. F., Norgren, R. B., Jr., Strauss, J. and El Sayed, M. A. (1994) Zinc, metallothionein, zinc fingers, and neurotrophic activity in neuroimmunoendocrine system. In: Pathophysiology of Immune-Neuroendocrine Communication Circuit, pp. 11-47. Eds. D. Gupta, H. A. Wollman and P. G. Freybergh. Mattes Verlag: Heidelberg.
16. Ebadi, M., Iversen, P. L., Hao, R., Cerutis, D. R., Rojas, P., Happe, H. K., Murrin, L. C. and Pfeiffer, R. F. (1995) Expression and regulation of brain metallothionein. Neurochem. Int. 27, 1-22.
17. Ebadi, M., Srinivasan, S. K. and Baxi, M. D. (1996a) Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48, 1-19.
18. Ebadi, M., Perini, F., Mountjoy, K. and Garvey, J. S. (1996b) Amino acid composition, immunoreactivity, sequence analysis, and function of bovine hippocampal metallothionein isoforms. J. Neurochem. 66, 2121-2127.
19. Ebadi, M., Hiramatsu, M. and Rojas, P. (1996c) Zinc and metallothionein isoforms in free radical-mediated striatal damage in Parkinson's disease. In: Free Radicals in Brain Physiology and Disorders, pp. 141-156. Eds. L. Packer, M. Hiramatsu and T. Yoshikawa. Academic Press.
20. Forno, L. (1986) The Lewy body in Parkinson's disease. Adv. Neurol. 45, 35-43.
21. Goeth, M. E., Freyberger, A. and Riederer, P. (1990) Oxidative stress: A role in the pathogenesis of Parkinson's disease. J. Neural. Transm. 29, 241-249.
22. Griscavage, J. M., Rogers, N. E., Sherman, M. P. and Ignarro, L. J. (1993) Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J. Immunol. 151, 6329-6337.
23. Hao, R., Ebadi, M. and Pfeiffer, R. F. (1995) Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Neurosci. Lett. 200, 77-80.
24. Hattori, N., Tanaka, M. and Ozawa, T. (1991) Immunohistochemical studies in complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30, 563-571.
25. Heikkila, R. E., Nicklas, W. L. and Vyas, I. (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implications for the mechanism of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine toxicity. Neurosci. Lett. 62, 389-394.
26. Hornykiewicz, O. (1988) Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. Mt Sinai J. Med. 55, 11-20.
27. Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y. and Hirsch, E. C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363.
28. Javitch, J. A., D'Amato, R. J., Strittmatter, S. M. and Snyder, S. H. (1985) Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173-2177.
29. Jellinger, K. (1986) An overview of morphological changes in Parkinson's disease. Adv. Neurol. 45, 1-16.
30. Jellinger, K. (1987) The pathology of parkinsonism. In: Movement Disorders, pp. 124-165. Eds. C. D. Marsden and S. Fahn. Butterworths: London.
31. Kopin, I. J. and Schoenberg, D. G. (1988) MPTP in animal models of Parkinson's disease. Mt. Sinai J. Med. N. Y. 55, 43-49.
32. Louis, E. D., Goldman, J. E., Powers, J. M. and Fahn, S. (1995) Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Move. Disorders 10, 188-194.
33. Maret, W. (1994) Oxidative metal release from metallothionein via zinc-thiot/disulfide interchange. Proc. Natl. Acad. Sci. USA 91, 237-241.
34. Maret, W. (1995) Metallothionein/disulfide interactions, oxidative stress, and the mobilization of cellular zinc. Neurochem. Int. 27, 111-117.
35. +, inhibit mitochondrial NADH-ubiquinone oxidoreductase activity. Proc. Jap. Acad. Series B - Phys. Biol. Sci. 62, 261-263.
36. Mitzuno, Y., Sone, N. and Saitoh, T. (1987) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48, 1787-1793.
37. Mitzuno, Y., Ohta, S. and Tanaka, M. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Comm. 163, 1450-1455.
38. Mitzuno, Y., Suzuki, K. and Ohta, S. (1990) Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J. Neurol. Sci. 96, 49-57.
39. +) is toxic to mesencephalic dopamine neurons in culture. Neurosci. Lett. 57, 19-24.
40. Perry, T. L. and Young, V. W. (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
41. Perry, T. L., Godin, D. V. and Hansen, S. (1982) Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
42. Polymeropolous, M. H., Lavedan, C., Leroy E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropouls, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I. and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
43. 3H-pargyline binding to MAO. Brain Res. 330, 337-343.
44. Riederer, P., Konradi, C., Hebenstreit, G. and Youdim, M. B. H. (1989a) Neurochemical perspectives to the function of monoamine oxidase. Acta. Neurol. Scand. 80, 41-45.
45. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K. and Youdim, M. B. H. (1989b) Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brain. J. Neurochem. 52, 515-520.
46. Rofe, A. M., Philcox, J. C. and Coyle, P. (1996) Trace metal, acute phase and metabolic response to endotoxin in metallothionein-null mice. Biochem. J. 314, 793-797,
47. Rojas, P. and Ríos. C. (1997) Metallothionein inducers protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. Neurochem. Res. 22, 17-22.
48. Rojas, P., Cerutis, D. R., Happe, H. K., Murrin, L. C., Hao, R., Pfeiffer, R. F. and Ebadi, M. (1996) 6-Hydroxydopamine-mediated induction of rat brain metallothionein I mRNA. NeuroToxicoiogy 17, 323-334.
49. Saggu, H., Cooksey, J. and Dexter, D. (1989) A selective increase in participate superoxide dismutase activity in Parkinsonian-substantia nigra. J. Neurochem. 53, 692-697.
50. Sawada, J., Kikuchi, Y., Shibutani, M., Mitsumori, K., Inoue, K. and Kasahara, T. (1994) Induction of metallothionein in astrocytes by cytokines and heavy metals. Biol. Signals 3, 157-168.
51. Schapira, A. H. V., Cooper, J. M. and Dexter, D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
52. Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B. and Marsden, C. D. (1990) Anatomic and disease specificity of NADH CoQ reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 2142-2145.
53. Schwarz, M. A., Lazo, J. S., Yalowich, J. C., Allen, W. P., Whitmore, M., Bergonia, H. A., Tzeng, E., Billiar, T. R., Robins, P. D., Lancaster, J. R., Jr. and Pitt, B. R. (1995) Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc. Natl. Acad. Sci. USA 92, 4452-4456.
54. Singer, T. P., Castagnoli, N., Ramsay, R. R. and Trevor, A. J. (1987) Biochemical events in development of Parkinson is in induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49, 1-8.
55. Smith, T. S., Parker, W. D., Jr. and Bennett, J. P., Jr. (1994) L-DOPA increases nigral production of hydroxyl radicals in vivo: Potential L-DOPA toxicity? NeuroReport. 5, 1009-1011.
56. Sofic, E., Lange, K. W., Jellinger, K. and Riederer, P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
57. Spina, M. B. and Cohen, G. (1989) Dopamine turnover and glutathione oxidation. Implications for Parkinson's disease. Proc. Natl. Acad. Sci. USA 86, 1398-1400.
58. Stuehr, D. J., Kwon, N. S. and Nathan, C. F. (1990) FAD and GSH participate in macrophage synthesis of nitric oxide. Biochem. Biophys. Res. Commun. 168, 558-565.
59. Tamai, K. T., Gralla, E. B., Ellerby, L. M., Valentine, J. S. and Thiele, D. J. (1993) Yeast and mammalian metallothioneins functionally substituted for yeast copper-zinc superoxide dismutase. Proc. Natl. Acad. Sci. USA 90, 8013-8017.
60. Wilhelmsen, K., Mirel, D., Marder, K., Bernstein, M., Naini, A., Leal, S.M., Cote, L.J., Tang, M.-X., Freyer, G., Graziano, J. and Mayeux, R. (1997) Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann. Neurology 41, 813-817.
61. Yoshikawa, T. (1993) Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33, 60-68.
62. Youdim, M. B. H. and Lavie, L. (1994) Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci. 55, 2077-2082.
63. Youdim, M. B. H., Ben-Shachar, D. and Riederer, P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. 26, 47-54.
64. Youngster, S. K., McKeown, K. A., Jin, Y. Z., Ramsay, R. R., Heikkila, R. E. and Singer, T. P. (1989) Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J. Neurochem. 53, 1837-1842.